Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results

PURCHASE, N.Y., Feb 11, 2008 /PRNewswire-FirstCall via COMTEX/ -- Nutrition 21, Inc. (NXXI) , the developer and marketer of nutritional supplements under the Chromax(R), Diabetes Essentials(TM) and Iceland Health(R) brands that help consumers manage blood sugar levels, improve cardiovascular health, enhance memory and reduce chronic joint pain, today announced financial results for the second quarter of fiscal year 2008 ended December 31, 2007.

The Company reported a 43% increase in total revenues to $13.0 million compared to $9.1 million in the comparable quarter a year ago. For the quarter, the Company's operating loss of $2.8 million represents a $1.6 million improvement over the year-ago period. Financial results for the quarter were impacted by a $2.4 million increase in advertising and promotion to support the launch of new products and a $0.7 million increase in net interest expense. Net loss for the quarter was $3.8 million, or $(0.06) per fully diluted share, compared to the net loss of $4.7 million, or $(0.08) per fully diluted share in the second quarter of fiscal year 2007.

Total revenues for the six months ended December 31, 2007 increased 83% to $25.2 million compared to $13.8 million in the same period a year ago. The Company's six-month operating loss was $6.5 million which is a $1.5 million improvement over the prior year. Net loss for the six months ended December 31, 2007 was $7.9 million, or $(0.13) per fully diluted share, compared to $8.8 million, or $(0.16) per fully diluted share, in the comparable period a year ago.

Paul Intlekofer, president and chief executive officer of Nutrition 21, Inc., said, "We are pleased with the progress that was achieved during the quarter in terms of growing revenues strongly while meaningfully reducing our operating loss. Going forward, we look to make consistent progress on top-line revenues, while we place continued emphasis on achieving profitability in an optimal timeframe."

"We are particularly pleased that during the quarter our Core4Life(TM) Advanced Memory Formula(TM) product is the fastest growing product in its segment at one of the nation's leading drugstore chains. In January we increased our distribution of Advanced Memory Formula by an additional 6,500 retail store locations, bringing the total number of retail stores locations to 20,500. As the median age of the U.S. population continues to increase, our focus group studies with middle-aged participants indicate that there is a strong desire to maintain the highest level of cognitive function and memory. Our Core4Life Advanced Memory Formula is aimed directly at this large and growing market and has been effective in clinical studies.
"Additionally, our new Diabetes Essentials brand continues to grow as awareness of the product line and its benefits begin to take hold. We are also working to develop an additional distribution channel for this product line in order to embed these products within the diabetes community nationwide. We believe that the Diabetes Essentials suite of products offers those suffering with diabetes a unique and pleasant approach to managing their nutritional requirements and improving the quality of their lives on an on-going basis."

Mr. Intlekofer concluded, "We continue to be pleased with the retail acceptance of the Iceland Health products. We also look forward to having our Iceland Health Joint Relief and Iceland Health Omega-3 products featured in displays and/or end-caps at a major national drugstore retailer in the month of March and at another large national drugstore retail chain in the month of April. In January, we increased our distribution channel for Iceland Health Joint Relief products by an additional 7,000 retail store locations, bringing to 23,000 stores offering the product. As focus group studies indicate, maintaining healthy and functional joints is a major concern, particularly within the "Baby Boom" generation, in order to remain as active and independent as possible for as long as possible. As clinical studies indicate, our Iceland Health Joint Relief product delivers the benefits that this active group is looking for. We are dedicated to developing this large and growing market in the years to come."

About Nutrition 21
Nutrition 21, Inc. (NXXI) , headquartered in Purchase, NY, is a nutritional bioscience company and the maker of chromium picolinate-based and omega-3 fish oil-based supplements with health benefits substantiated by clinical research. Nutrition 21 holds more than 30 patents for nutrition products and uses. Nutrition 21's portfolio of health and wellness brands include: Chromax(R), Core4Life(TM) Advanced Memory Formula(TM), Diabetes Essentials(TM), Iceland Health(R) Maximum Strength Omega-3 and Iceland Health(R) Joint Relief. The company also manufactures private label supplements and ingredients for third parties. Nutrition 21 distributes its products nationally through more than 29,000 major food, drug and super center retailers as well as internationally. For more information please visit

Safe Harbor Provision
This press release may contain certain forward-looking statements. The words "believe," "expect," "anticipate" and other similar expressions generally identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based largely on the Company's current expectations and are subject to a number of risks and uncertainties, including without limitation: the effect of the expiration of patents; regulatory issues; uncertainty in the outcomes of clinical trials; changes in external market factors; changes in the Company's business or growth strategy or an inability to execute its strategy due to changes in its industry or the economy generally; the emergence of new or growing competitors; various other competitive factors; and other risks and uncertainties indicated from time to time in the Company's filings with the Securities and Exchange Commission, including its Form 10-K/A for the year ended June 30, 2007. Actual results could differ materially from the results referred to in the forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the results referred to in the forward-looking statements contained in this press release will in fact occur. Additionally, the Company makes no commitment to disclose any revisions to forward-looking statements, or any facts, events or circumstances after the date hereof that may bear upon forward-looking statements.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.